{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=2&state=Wisconsin", "query": { "state": "Wisconsin", "city": "Milwaukee", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=1&state=Wisconsin&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T11:48:37.754Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00040027", "title": "Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a", "type": "DRUG" }, { "name": "placebo + PEGinterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciClone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2002-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-01-15", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 46, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040027" }, { "nct_id": "NCT02927769", "title": "A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "brentuximab vedotin", "type": "BIOLOGICAL" }, { "name": "bendamustine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "5 Years to 30 Years" }, "enrollment_count": 72, "start_date": "2017-03-28", "completion_date": "2024-05-28", "has_results": true, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02927769" }, { "nct_id": "NCT01823497", "title": "Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Abdominal Surgery", "Thoracic Surgery" ], "interventions": [ { "name": "Morphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Minute", "maximum_age": "70 Days", "sex": "ALL", "summary": "1 Minute to 70 Days" }, "enrollment_count": 36, "start_date": "2013-04", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01823497" }, { "nct_id": "NCT05537220", "title": "Oral N-acetylcysteine for Retinitis Pigmentosa", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Retinitis Pigmentosa" ], "interventions": [ { "name": "N-acetylcysteine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 485, "start_date": "2023-10-11", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 24, "location_summary": "Davis, California • Los Angeles, California • San Francisco, California + 21 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05537220" }, { "nct_id": "NCT01609582", "title": "Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Cardiovascular Disease" ], "interventions": [ { "name": "TAK-875", "type": "DRUG" }, { "name": "TAK-875 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3207, "start_date": "2012-06", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609582" }, { "nct_id": "NCT04214262", "title": "Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2020-08-13", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 391, "location_summary": "Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214262" }, { "nct_id": "NCT05343988", "title": "Percutaneous Neurostimulation to Treat Paroxysmal Sympathetic Hyperactivity in Children", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Paroxysmal Sympathetic Hyperactivity" ], "interventions": [ { "name": "Percutaneous Electrical Nerve Field Stimulation (PENFS) device application", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 20, "start_date": "2022-09-22", "completion_date": "2025-11-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05343988" }, { "nct_id": "NCT02898454", "title": "Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)" ], "interventions": [ { "name": "Dupilumab SAR231893 (REGN668)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate nasal spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2016-11-28", "completion_date": "2018-11-16", "has_results": true, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02898454" }, { "nct_id": "NCT04138394", "title": "VItamin C in Thermal injuRY: The VICToRY Trial", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Shock", "Thermal Burn" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clinical Evaluation Research Unit at Kingston General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 666, "start_date": "2020-07-24", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Bridgeport, Connecticut • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138394" }, { "nct_id": "NCT00227305", "title": "Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia", "Bipolar I Disorder" ], "interventions": [ { "name": "quetiapine fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 381, "start_date": "2004-08", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2013-01-08", "last_synced_at": "2026-06-07T11:48:37.754Z", "location_count": 31, "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227305" } ] }